Novo Nordisk to Acquire Emisphere Technologies for $1.8B

November 6, 2020 Auto Bot Acquire, M&A, Novo Nordisk 0

Shots:

  • Novo Nordisk to acquire all outstanding shares of Emisphere for $1.35B and also acquires royalty stream obligations to the firm’s biggest shareholder (MHR) for $450M, making a total deal value as $1.8B
  • Novo Nordisk eliminates its future royalty obligations to Emisphere and MHR & obtains full access to the Eligen SNAC technology platform, thus enabling Novo Nordisk to expand its portfolio of oral biologics across therapy areas
  • The acquisition will provide Novo Nordisk full rights of the Eligen’s SNAC technology, which has been used under a 2007 license agreement to develop the first oral biologic, Rybelsus for T2D

Click here ­to­ read full press release/ article | Ref: Novo Nordisk | Image: SRX

The post Novo Nordisk to Acquire Emisphere Technologies for .8B first appeared on PharmaShots.